Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
Today's milestone builds on our heritage of developing and delivering novel treatments for patients with advanced renal cell carcinoma, first with the only dual immunotherapy option, Opdivo plus Yervoy, and ... now with a new immunotherapy and tyrosine
Latest news
-
Opdivo improves survival in oesophageal cancer
The FDA has set a prescription drug user fee act (PDUFA) goal date for a decision on BMS’ immunotherapy regimen of 25 May.
-
Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
with early-stage, resectable non-small cell lung cancer,” said Patrick Forde, associate professor, Sidney Kimmel Comprehensive Cancer Center and Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University.
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
The CAR T cell therapy will be manufactured for each individual patient at BMS’ cellular immunotherapy manufacturing facility in Summit, New Jersey. .
-
Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer
Merck &Co’s immunotherapy treatment is the first checkpoint inhibitor to show superior overall survival, progression-free survival and objective response rates for this patient population – regardless of PD-L1 expression
-
Roche’s Tecentriq yields positive data in early stage NSCLC
With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning," said Levi Garraway, chief medical ... Keytruda has become a new standard-of
More from news
Approximately 99 fully matching, plus 531 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
The global pharmaceutical and biotechnology industries have achieved many significant milestones in innovative research and drug development in the past decade – including the broad adoption of immunotherapies and the introduction of
-
Switzerland: a life sciences hub
For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines.
-
Cortellis Drugs to Watch in 2020 report
Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).
-
Pharma funding and M&A in 2020
Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for ... Indeed, a key theme of the deals I have mentioned
-
It started with a miss
However, we’re now moving into areas like immunotherapy and are on the edge of amazing innovations that will deliver great outcomes for patients.
More from intelligence
Approximately 5 fully matching, plus 57 partially matching documents found.
Latest appointments
-
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
-
New hires at Crescendo, Healx and Galecto
He joins Galecto from eTheRNA immunotherapies, a Belgian mRNA immunotherapy company.
-
New hires at bluebird bio, BioNTech and Provention Bio
In his role as CCO at Provention, Hoitt will be responsible for the development and execution of the company’s global commercial strategy for its type 1 diabetes prevention immunotherapy
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
More from appointments
Approximately 2 fully matching, plus 47 partially matching documents found.
Latest from PMHub
-
The impact of COVID-19 on cancer care
Management. Patients with cancer, particularly those receiving chemotherapy, radiotherapy and/or immunotherapy, are at an increased risk of the symptoms and long-term effects of COVID-19 compared with their healthy
-
September 2020: diversity and inclusion in clinical trials round-up
If you see the major immunotherapy trials published, there are few Hispanics or Blacks included in the US trials, despite the fact that together they are close to 30% of the
-
In the precision medicine era, the line between products and services is blurred
CAR-T is a new individualised cancer immunotherapy that has taken precision medicine to a new level.
-
Precision paediatrics: Treating patients with CAR-T
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
-
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
More from PMHub
Approximately 11 fully matching, plus 17 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Associate Account Director
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Medical Writer
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- GSK discontinues two feladilimab trials in head and neck cancer
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Roche’s Ocrevus shows significant benefit in early-stage MS patients
- Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
- Leaders in Pharma: Samir Vattompadam
- Building Better Access to Pediatric Care Through Telehealth
- Building trust through sustainability communications
- Healthware Group acquires London-headquartered consultancy SWM
- Lucid Group promotes Clare Reynolds to Director of Business Development and Commercial Integration
- Are you ready for the digital health revolution?
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Are you ready for the digital health revolution?
- In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
- #DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
- Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
- Empowering patients empowers results
- Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Quick links
Infographics
